Intratumoral oxygen tension in metastatic melanoma

Melanoma Research

Volumn 7, Issue 5, 1997, Pages 400-406

  Lartigau, E ^a   Randrianarivelo, H ^a   Avril, M F ^a   Margulis, A ^a   Spatz, A ^a   Eschwege F ^a   Guichard, M ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Hypoxia; Melanoma; PO2

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INVASION; CLINICAL ARTICLE; FEMALE; HUMAN; HYPOXIA; MALE; MELANOMA; METASTASIS POTENTIAL; OXYGEN TISSUE LEVEL; PRIORITY JOURNAL; SKIN BIOPSY;

EID: 0030694237     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199710000-00006     Document Type: Article

References (42)

1. Popescu NA., Beard CM, Treacy PJ, Winkelmann RK, O'Brien P, Kurland LT. Cutaneous malignant melanoma in Rochester, Minnesota: trends in incidence and survivorship, 1950 through 1985. Mayo Clin Proc 1990; 65: 1293-1302.
2. MacKie R, Hunter JAA, Aitchison TC et al. Cutaneous melanoma, Scotland, 1979-89. Lancet 1992; 339: 971-972.
3. Balch CM, Urist MM, Karakousis CP et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Ann Surg 1993; 3: 262-269.
4. Ho RCS. Medical management of stage IV malignant melanoma: medical issues. Cancer 1995; 75: 735-741.
5. Jacquillat C, Khayat D, Banzet P et al. Final report of the French multicentric phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990; 9: 1873-1878.
6. Veronesi U, Adamus J, Aubert C et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982; 15: 9413-9416.
7. Peschel RE. Radiobiology and radiation treatment of malignant melanoma: a review. Radiat Oncol Invest 1994; 1: 249-260.
8. Trott KR, von Lieven H, Kummermehr J, Skopal D, Lukacs S, Braun-Falco O. The radiosensitivity of malignant melanomas. I. Experimental studies. Int J Radiat Oncol Biol Phys 1981; 7: 9-13.
9. Trott KR, von Lieven H, Kummermehr J, Skopal D, Lukacs S, Braun-Falco O, Kellerer AM. The radiosensitivity of malignant melanomas. II. Clinical studies. Int J Radiat Oncol Biol Phys 1981; 7: 15-20.
10. Habermalz HJ. Irradiation of malignant melanoma: experience in the past and present. Int J Radiat Oncol Biol Phys 1981; 7: 131-133.
11. Overgaard J, Gonzalez Gonzalez D, Arcangeli G, Dahl O, Bentzen SM. ESHO protocol 3-85. A multicenter randomized trial evaluation of hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. Abstracts, ESHO Meeting, Brussels, June 1993.
12. Adam JS, Habeshaw T, Kirk J. Response rate of malignant melanoma to large fraction irradiation. Br J Radiol 1982; 55: 605-607.
13. Overgaard J, Overgaard M, Hansen PV, von der Maase H. Some factors of importance in the radiation treatment of malignant melanoma. Radiother Oncol 1986; 5: 183-192.
14. Strauss A, Dritschilo A, Nathanson L, Piro AJ. Radiation therapy of malignant melanomas: an evaluation of clinically used fractionation schemes. Cancer 1981; 47: 1262-1266.
15. Katz HR. The results of different fractionation schemes in the palliative irradiation of metastatic melanoma. Int J Radiat Oncol Biol Phys 1981; 7: 907-911.
16. Sause WT, Cooper JS, Rush S, Ago CT, Cosmatos D, Coughlin CT, Janjan N, Lipsett J. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 1991; 20: 429-432.
17. Ang KK, Byers RM, Peters LJ, Maor MH, Wendt CD, Morrison WH, Hussey DH, Goepfert H. Regional radiotherapy as adjuvant treatment for head and neck malignant melanoma. Arch Otolaryngol Head Neck Surg 1990; 116: 169-172.
18. Schaake-Koning CCE. Role of radiotherapy as treatment for malignant melanoma in the head and neck. Diag Oncol 1993; 3: 272-273.
19. Lartigau E, Guichard M, Ferradini C. Oxygène et radiations ionisantes. J Chim Phys 1994; 91: 1140-1148.
20. Chapman JD. Measurement of tumor hypoxia by invasive and non invasive procedures: a review of recent clinical studies. Radiother Oncol 1991; 20: 13-19.
21. Cater DB, Silver IA. Quantitative measurements of oxygen tension in normal tissues and in the tumors of patients before and after radiotherapy. Acta Radiol 1960; 53: 233-256.
22. Kolstad P. Intercapillary distance, oxygen tension and local recurrence in cervix cancer. Scand J Clin Lab Invest 1968; 106(suppl): 145-157.
23. Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Modofsky PJ, Hartz WH, Broder GJ. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1988; 10: 831-838.
24. 2 measurements with hypodermic needle probes. In: Ehrly AM, Fleckenstein W, Hauss J, Huch R, eds. Clinical Oxygen Pressure Measurement II. Blackwell Ueberreuter Wissenschaft, Berlin, 1990: 38-50.
25. Vaupel P. Oxygenation of human tumors. Stralenther Onkol 1990; 166: 377-386.
26. Lartigau E, Leridant AM, Lambin P, Weeger P, Martin L, Sigal R, Lusinchi A, Luboinski B, Eschwege F, Guichard M. Oxygenation of head and neck tumors. Cancer 1993; 71: 2319-2325.
27. Lartigau E, Randrianarivelo H, Martin L et al. Oxygen tension measurements in human tumors: the Institut Gustave-Roussy experience. Radiat Oncol Invest 1994; 1: 285-291.
28. Höckel M, Vorndran B, Schlenger K, Baussmann E, Knapstein PG. Tumor oxygenation: a new predictive parameter in locally advanced cancer of the uterine cervix. Gynecol Oncol 1993; 51: 141-149.
29. 2 measurement in vitro and in vivo. Int J Radiat Biol 1996, 69: 205-211.
30. Guichard M. Comparison of the radiobiological properties of human tumor xenografts and rodent tumors. Int J Radiat Biol 1989; 56: 583-586.
31. Coleman CN. Hypoxia in tumors: a paradigm for the approach to biochemical and physiological heterogeneity. J Natl Cancer Inst 1988; 80: 310-316.
32. Teicher BA, Lazo JS, Sartorelli AC. Classification of antineoplasic agents by their selective toxicities towards oxygenated and hypoxic tumor cells. Cancer Res 1981; 41: 73-81.
33. Kennedy KA. Hypoxic cells as specific drug targets for chemotherapy. Anticancer Drug Res 1987; 2: 181-194.
34. Dische S. Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy. Radiother Oncol 1985; 3: 97-115.
35. Guichard M. The use of fluorocarbon emulsions in cancer radiotherapy. Radiother Oncol 1991; (suppl 20): 59-64.
36. Denekamp J, Hill S. Angiogenic attack as a therapeutic strategy for cancer. Radiother Oncol 1991; (suppl 20): 103-112.
37. Overgaard J. Importance of tumor hypoxia in radiotherapy. A meta-analysis of controlled clinical trials. Radiother Oncol 1991; 24: S64.
38. Workman P, Stratford IJ. The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev 1993; 12: 73-82.
39. Brown JM. SR-4233 (tirapazamine). a new anticancer drug exploiting hypoxia in solid tumors. Br J Cancer 1993; 67: 1163-1170.
40. Weissberg JB, Son YH, Papac RJ, Sasaki C, Fischer DB, Lawrence R. Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. Int J Radiat Oncol Biol Phys 1989; 17: 3-9.
41. Koch CJ. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res 1993; 53: 3992-3997.
42. Lartigau E, Guichard M. Does tirapazamine (SR-4233) have any cytotoxic or sensitizing effect on 3 human cell lines at clinically relevant partial oxygen pressure? Int J Radiat Biol 1995; 2: 211-216.